Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti B7 H3 chimeric antigen receptor T-cell therapy - BoYuan RunSheng Pharma

Next Previous
Drug Profile

Anti B7 H3 chimeric antigen receptor T-cell therapy - BoYuan RunSheng Pharma

Alternative Names: Anti-B7-H3 CAR-T cell therapy - BoYuan RunSheng Pharma; B7-H3 CAR-T; BP-102 - BoYuan RunSheng Pharma

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Tian Tan Hospital; BoYuan RunSheng Pharma
  • Developer BoYuan RunSheng Pharma
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma

Most Recent Events

  • 12 May 2020 Phase-I clinical trials in Glioblastoma (Second-line therapy or greater, Recurrent) in China (Intracerebral) (NCT04385173)
  • 12 May 2020 Phase-I clinical trials in Glioblastoma (Second-line therapy or greater, Recurrent) in China (Intratumoural) (NCT04385173)
  • 01 May 2020 Phase-I/II clinical trials in Glioblastoma (Second-line therapy or greater, Combination therapy) in China (Intracerebral) (NCT04077866)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top